Expand ZYME Menu
ZYME MENU

ZYME Latest Press Releases

-- April 17, 2026 --

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform Globe Newswire 3:00 PM

-- April 16, 2026 --

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026 Globe Newswire 6:00 AM

-- April 9, 2026 --

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth Globe Newswire 6:00 AM

-- April 1, 2026 --

Zymeworks Appoints Kristin Stafford as Chief Financial Officer Globe Newswire 6:00 AM

-- March 30, 2026 --

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRa-Targeting Antibody-Drug Conjugate Globe Newswire 6:00 AM

-- March 24, 2026 --

Zymeworks Announces Participation in Upcoming Investor Conferences Globe Newswire 6:00 AM

-- March 18, 2026 --

Zymeworks Announces Presentations for Ziihera (zanidatamab-hrii) at 2026 AACR Annual Meeting Globe Newswire 7:46 AM

-- March 17, 2026 --

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting Globe Newswire 5:11 PM

-- March 2, 2026 --

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing Globe Newswire 6:10 AM
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing Globe Newswire 6:01 AM
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results Globe Newswire 6:00 AM

-- February 12, 2026 --

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 Globe Newswire 6:00 AM

-- January 27, 2026 --

Zymeworks Announces Participation in Upcoming Investor Conferences Globe Newswire 6:00 AM

-- January 12, 2026 --

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy Globe Newswire 6:00 AM

-- January 11, 2026 --

Zymeworks Outlines Strategic Priorities and Outlook for 2026 Globe Newswire 6:00 PM

-- January 6, 2026 --

Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit Globe Newswire 1:34 PM

-- December 2, 2025 --

Zymeworks Announces Participation in Upcoming Conferences Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes